PTC Therapeutics Insider Almstead Sells 5,323 Shares
PTC Therapeutics' Chief Technical Ops Officer sold 5,323 shares, reflecting insider activity.
Key Points
- On June 24, 2026, Almstead Neil Gregory, Chief Technical Ops Officer, sold 5,323 shares of PTC Therapeutics, Inc.
- PTC Therapeutics, Inc. has a market cap of $7.01 billion and a forward P/E ratio of 30.36, with shares trading near $84.51.
- Analysts like Citigroup and Jefferies have set price targets between $76 and $108, with a consensus 'buy' recommendation.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Almstead Neil Gregory, the Chief Technical Ops Officer at PTC Therapeutics, Inc. (NasdaqGS: PTCT), sold 5,323 shares. The transaction was not made under a pre-arranged trading plan, according to the insider filing.
Insider Buying and Selling at PTC Therapeutics, Inc.
Neil Gregory Almstead, serving as Chief Technical Ops Officer, executed several transactions involving PTC Therapeutics' shares. On June 24, 2026, he sold 5,323 shares. Additionally, on June 25, he sold another 20,960 shares at an average price of $85.97 under a planned transaction, while also acquiring 20,960 shares at $38.11.
PTC Therapeutics, Inc. Stock Up 20.5%
On Saturday, shares of PTC Therapeutics, Inc. (NasdaqGS: PTCT) traded near $84.51. The company, with a market cap of $7.01 billion, has a forward P/E ratio of 30.36 and a beta of 0.549. Over the past 52 weeks, the stock has ranged from $43.18 to $87.50. Its 50-day moving average is $72.01, and the 200-day moving average is $70.81. The company maintains a current ratio of 2.44 and a quick ratio of 2.29.
$PTCT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analyst activity has been robust for PTC Therapeutics. On June 9, 2026, Citigroup assumed coverage with a 'buy' rating and a $108 price target. Jefferies upgraded the stock to a 'buy' with an $85 target on May 27, while TD Cowen also upgraded it to 'buy' with a $90 target on May 8. The consensus among analysts is a 'buy' rating, with a mean price target of $93.93 based on 14 opinions.
About PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company based in Warren, New Jersey. It focuses on discovering, developing, and selling medicines for rare disorders affecting both children and adults. The company offers treatments like Translarna and Emflaza for Duchenne muscular dystrophy and Upstaza for AADC deficiency. PTC's product pipeline includes therapies for conditions like phenylketonuria and Huntington's disease. Founded in 1998, the company collaborates with several major pharmaceutical firms to advance its research and development efforts.
Bottom Line
Insider transactions like those by Almstead Neil Gregory provide a glimpse into the activities of company executives. PTC Therapeutics, with its focus on rare diseases, draws attention from investors and analysts alike. The stock's recent analyst ratings underscore its potential, though the backward-looking nature of these filings means the current insider stance might differ.
Get PTC Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PTCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.